Member Info for Steadydanny

Total agreement Mafuta.
I've been pondering today on the last subscription. Not too shabby by any account.
So I put myself in a position if I was a HNWI.
Well persons I've met and a few I know and a few who are Very well off. Including customers. Well they are probably the ones who are very very cautious with investment unless they have undertaken due diligence themselves or also using a third party...cough cough edison reports and peel hunt involved!
So why by all acccounts would they bring possibly mates in and add more to sareums bank account unless they were happy to add further investment for a worthwhile investment?
The recent 1802 patents imo will become apparent re licensing and we will pursue 1801 with re capsule methodology as being the Bentley. But 1802 will have great separate opportunities.
Sooner rather than later until 1801 capsule is approved.
Regards Steadydanny

Hi ahfam. Maybe 1801 into clinical. 1802 into licensing! ;-) hence the Patents and submarine patent. Its unfurling. Back to wilber Smith. Best regards Steadydanny

Spot on fearg . If there's commotion we are in motion.

So we get extra investment ...that's encouragingimo...from yesterday I posted this...

This is what I'm amazed has not been shouted from the rooftops16 Dec 2021 17:36

From earlier RNS today as I guessed the results were in. Still a few minor formalities but...

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801

Why this is not on a news report such as proactive seems to me we are being deliberately held back re sp and mc. And this also means 1802 is worth more due to similarity as advised in previous q and a.
Hence the 1802 patent upgrade in Europe and recent one in USA.
So we get a RNS today re extra investors investment. Tyk tok

Extract today
Cambridge, UK, 17 December 2021 - Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development company, announces that it has raised approximately £1.63 million, before expenses, through a subscription by new and existing high net worth individuals

Notice they say' new and existing 'not 'a' new investor.
Hence more than one new HNWI investor with existing HNWIs subscribers.
Taking on the big boys. Probably names with gravitas. You don't back a donkey at Cheltenham
1801 similar to 1802 as advised in previous q and a and thus will move forward quickly. Hence new patents. Delay on 1801 as sareum want it perfect!
I'm reckoning on licensing deals before Q1 2022 with 1802.
Sorry for kicking off last night but I could smell some of the posters were playing games and heyho next day we get a RNS of significant funding to make us more of a backed player.
Best regards Steadydanny

Let's hope so jima!

Sorry Jima. Completely misread. Sincere apologies. 100percent apology.
737 looks interesting and 1801 and more initially 1802 looks quite promising.

And they have been spot on thoth with predictions!? Do you understand how much they are costing the economy with previous wrong predictions? You sat in your ivory tower? Wake up call from tin hatter.
I came on here reading your scientific reasons and lth views to be invested here. Amongst others. You seem to be the only one who is critical and derogatory to genuine questions. And might I add actually never have a plausible response.
I've always responded. Stand my ground. You just post juvenile type YouTube posts to prevent a reasoned response.
Binned.
Thoth you are no longer thank God in my discussion points.

Take 2 minutes and look at Sareum's strategy on their website.

London they should also be aware that they have involved 3rd party consultants
This

We are particularly pleased to have raised substantial additional funding that will be deployed to advance these programmes into clinical development and build a robust data package that will add momentum to our ongoing partnering activities for these exciting and differentiated assets.

Now it's where it gets interesting
Norwich Pharmacal Order
A Norwich Pharmacal order is a court order for the disclosure of documents or information that is available in the United Kingdom and Ireland. It is granted against a third party which has been innocently mixed up in wrongdoing, forcing the disclosure of documents or information.

So if Sareum stick it to us we can access all parties involved in using sareum raised money for a very effective court case.
But I think Mr Parker is onside.

Glenmore I take consulation in the 25th October RNS
The Board and management continue to employ rigorous capital allocation in the development of internal assets and the overall business, with a clear focus on generating value for shareholders.

We would like to thank our shareholders, suppliers, contractors and other stakeholders for their continued support and look forward to providing further updates on progress as we move forward in 2021 and 2022.

If they did anything than they purport on their website then they are nuts deep in court cases from shareholders and would be investigated for pecuniary advantage...be it themselves or NOMAD advisors.
;-)

 

Dr Stephen Parker                                                                                           Dr Tim Mitchell

Chairman           

That's 1802 as per recent European patent update!
From earlier RNS today
With regards to our second TYK2/JAK1 inhibitor candidate, SDC-1802, we continue to advance the preclinical development of an oral formulation and have designed and initiated translational studies to define the optimal cancer application prior to completing toxicology and manufacturing studies.
It will be the same as the toxicology results accepted by the board in today's RNS as in 1801 but a few formalities but happy to go forward with 1801 CTA!!
I'm expecting this to hit the moon. So much in the statements that I could mention that dovetail. Pretty sure SOG is on it. Ps love your posts SOG.
Ps when they say Q1 2022 that could be what Monday 3rd January?
Oh my goodness. So we will move forward with 1802 whilst the Bentley is in the workshop being fine tuned!!
Knew it.
Brilliant xxx

Evening Celtic. That is only half of the picture.!! ;-)
From our Web page is this..
Our strategy

Sareum’s strategy is to develop programmes to late preclinical or early clinical stages to take advantage of the higher asset values associated with licensing programmes at these stages.

ApproachBenefit
Pursue multiple programmes
Increase potential success rate
Mitigate development risk
Seek collaboration partners
Spread financial cost and risk
Introduce specialist research expertise

Develop programmes to pre-clinical/
early clinical development

Minimise ongoing development risk
Move up value chain
Potential for higher deal values

When others join the dots. This is a mind blowing point in Sareums history so far.
I can smell licensing contracts re 1801 and 1802 and as for the rest of it...well RMMs calculator will be smoking I reckon. More irons in the fire than a blacksmith.
Best regards Steadydanny

From earlier RNS today as I guessed the results were in. Still a few minor formalities but...

We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801

Why this is not on a news report such as proactive seems to me we are being deliberately held back re sp and mc. And this also means 1802 is worth more due to similarity as advised in previous q and a.
Hence the 1802 patent upgrade in Europe and recent one in USA.
Regards The Tin Hatter :-)
Looks good to me

Flt3 will bring up censorship here. Let's see if I say professor Charles Lieber of Harvard University, 1000 talents program, wuhan military games.....tick tock tyk tok.
Previous ones got deleted.

Stand by everything I've said. I'm not afraid of being of an opinion. Standing firm on opinion observations and research.
Too many not seeing the drip of discussion being disputed without properly being discussed with reasoned responses being kicked aside.
Yes I'm here for cytokine storms and cytotoxicity and cytosine uracil and tyrosine conflicts.
Peace out.

Just a thought. 1801 has been delayed as pursuing capsule route. As in previous RNS they advised subject to toxic results. We were also advised in the q and a that 1802 was very similar to 1801 and would progress rapidly with 1801 progress.
So just my thought that this euro patent application post the US one is maybe a sign the toxicology results are in and good? Im guessing RNS soon. Maybe this afternoon. And that 1802 is going the original route 1801 was but not so sophisticated but still very effective.
As in the Bentley is in the workshop being fine tuned but in the meantime we have let the dependable volvo out to early playtime in the pharma radar arena.
Just a thought.

I'm assuming from this that 1801 is all tickety boo as remember in q and a they said we were fully funded to progress 1801 and 1802 would follow quickly due to their similarities!!
Looking good to me!!

This is regards Peel Hunt
Cambridge, UK, 29 October 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, is pleased to announce the appointment of Peel Hunt LLP as a Joint Corporate Broker with immediate effect. Strand Hanson Limited and Hybridan LLP will continue to act as the Company's Nominated Adviser and Joint Corporate Broker, respectively.
And this
What Is a Nominated Advisor (NOMAD)?

A nominated advisor (NOMAD) is a financial services firm that assists with listing a company onto the Alternative Investment Market (AIM) of the London Stock Exchange (LSE). The Alternative Investment Market is a specialized unit of the LSE catering to smaller, more risky companies.

The LSE requires that a company seeking a listing on AIM have a NOMAD, which the LSE itself must approve to carry out the functions. Once listed on the AIM, the NOMAD oversees the company and ensures it follows regulations. NOMADs are thus seen as the regulatory system for the less-stringent AIM market and are tasked with advising companies both pre-IPO and after listing.

Best regards Steadydanny

The delay im referring to num4 is a capsule where a pill could be ongoing with potential limited response. But still a market of capitalisation for sareum as work in progress for a capsule formulation that works better.
Why hold back?
We are being held back deliberately imo.
Ps my mum was a nanny for the cadburys in 1971 in Cornwall and their other homes. The younger ones used to enjoy a speedboat ride and got on well with my then to be mum.
Anyhow best wishes tomorrow all.
That's fact !